184 related articles for article (PubMed ID: 23377553)
1. Development of breast cancer-related lymphedema: is it dependent on the patient, the tumor or the treating physicians?
Morcos B; Ahmad FA; Anabtawi I; Sba' AM; Shabani H; Yaseen R
Surg Today; 2014 Jan; 44(1):100-6. PubMed ID: 23377553
[TBL] [Abstract][Full Text] [Related]
2. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients.
Helyer LK; Varnic M; Le LW; Leong W; McCready D
Breast J; 2010; 16(1):48-54. PubMed ID: 19889169
[TBL] [Abstract][Full Text] [Related]
3. The incidence and risk factors for occurrence of arm lymphedema after treatment of breast cancer.
Rebegea L; Firescu D; Dumitru M; Anghel R
Chirurgia (Bucur); 2015; 110(1):33-7. PubMed ID: 25800313
[TBL] [Abstract][Full Text] [Related]
4. Lymphedema following breast cancer treatment, including sentinel lymph node biopsy.
Armer J; Fu MR; Wainstock JM; Zagar E; Jacobs LK
Lymphology; 2004 Jun; 37(2):73-91. PubMed ID: 15328760
[TBL] [Abstract][Full Text] [Related]
5. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
6. A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy.
Kim M; Kim SW; Lee SU; Lee NK; Jung SY; Kim TH; Lee ES; Kang HS; Shin KH
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):498-503. PubMed ID: 23541809
[TBL] [Abstract][Full Text] [Related]
7. The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients.
Ikeda K; Ogawa Y; Kajino C; Deguchi S; Kurihara S; Tashima T; Goto W; Nishiguchi Y; Tokunaga S; Fukushima H; Inoue T
Eur J Surg Oncol; 2014 Jul; 40(7):818-23. PubMed ID: 24768416
[TBL] [Abstract][Full Text] [Related]
8. The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study.
Soran A; Ozmen T; McGuire KP; Diego EJ; McAuliffe PF; Bonaventura M; Ahrendt GM; DeGore L; Johnson R
Lymphat Res Biol; 2014 Dec; 12(4):289-94. PubMed ID: 25495384
[TBL] [Abstract][Full Text] [Related]
9. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy.
Nesvold IL; Dahl AA; Løkkevik E; Marit Mengshoel A; Fosså SD
Acta Oncol; 2008; 47(5):835-42. PubMed ID: 18568481
[TBL] [Abstract][Full Text] [Related]
10. Time trend of breast cancer-related lymphedema according to body mass index.
Ogiya A; Kimura K; Ueno T; Iwase T; Ohno S
Eur J Surg Oncol; 2024 Jun; 50(6):108350. PubMed ID: 38653160
[TBL] [Abstract][Full Text] [Related]
11. Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience.
Yang EJ; Ahn S; Kim EK; Kang E; Park Y; Lim JY; Kim SW
Breast Cancer Res Treat; 2016 Nov; 160(2):269-276. PubMed ID: 27665585
[TBL] [Abstract][Full Text] [Related]
12. Risk of lymphedema after regional nodal irradiation with breast conservation therapy.
Coen JJ; Taghian AG; Kachnic LA; Assaad SI; Powell SN
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1209-15. PubMed ID: 12654429
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.
Mansel RE; Fallowfield L; Kissin M; Goyal A; Newcombe RG; Dixon JM; Yiangou C; Horgan K; Bundred N; Monypenny I; England D; Sibbering M; Abdullah TI; Barr L; Chetty U; Sinnett DH; Fleissig A; Clarke D; Ell PJ
J Natl Cancer Inst; 2006 May; 98(9):599-609. PubMed ID: 16670385
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.
McLaughlin SA; Wright MJ; Morris KT; Giron GL; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
J Clin Oncol; 2008 Nov; 26(32):5213-9. PubMed ID: 18838709
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors.
Terada M; Yoshimura A; Sawaki M; Hattori M; Naomi G; Kotani H; Adachi Y; Iwase M; Kataoka A; Sugino K; Mori M; Horisawa N; Ozaki Y; Iwata H
Breast Cancer Res Treat; 2020 Jan; 179(1):91-100. PubMed ID: 31535321
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer-related lymphedema after axillary lymph node dissection: does early postoperative prediction model work?
Soran A; Menekse E; Girgis M; DeGore L; Johnson R
Support Care Cancer; 2016 Mar; 24(3):1413-9. PubMed ID: 26349574
[TBL] [Abstract][Full Text] [Related]
17. Using the axillary reverse mapping technique to screen breast cancer patients with a high risk of lymphedema.
Liu S; Wang N; Gao P; Liu P; Yang H; Xie F; Wang S; Liu M; Wang S
World J Surg Oncol; 2020 Jun; 18(1):118. PubMed ID: 32482174
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration.
Aoishi Y; Oura S; Nishiguchi H; Hirai Y; Miyasaka M; Kawaji M; Shima A; Nishimura Y
Breast Cancer; 2020 Sep; 27(5):929-937. PubMed ID: 32270417
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery.
Miller CL; Specht MC; Skolny MN; Jammallo LS; Horick N; O'Toole J; Coopey SB; Hughes K; Gadd M; Smith BL; Taghian AG
Breast Cancer Res Treat; 2012 Oct; 135(3):781-9. PubMed ID: 22941538
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.
McLaughlin SA; Wright MJ; Morris KT; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
J Clin Oncol; 2008 Nov; 26(32):5220-6. PubMed ID: 18838708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
